Sekisui Chemical Co., Ltd.

Sekisui Medical Co., Ltd.

Nof Corporation

Takayuki Akamine

Saori Tone

Kazushi Itou

Yoshiko Abe

Daichi Kawamura

Yuuta Nakamura

Katsumi Yoshikawa

Akihiko Fujiwara

Taro Suzuki

Shinichiro Kitahara

Izumi Matsumoto

Michiko Kawamoto

Masayuki Yokoi

Yasuyuki Hara

Tomoki Toda

Yan Li

Tetsuya Ota

Yuudai Ogata

Provided is a core-shell structure having an excellent immediate effect in transdermal absorption of an active ingredient. A core-shell structure comprising a core portion containing an active ingredient, and a shell portion containing a surfactant having an HLB value of 4 to 14, the core portion being solid, and the surfactant containing a saturated hydrocarbon group having 7 to 15 carbon atoms or an unsaturated hydrocarbon group having 7 to 17 carbon atoms.

Core-shell structure, preparation, medicine for external application, tape agent and cosmetic product

Provided is an external skin preparation capable of enhancing permeability of an active ingredient into parts of the epidermis located below the stratum corneum and the dermis even when a poorly water-soluble active ingredient is used. There is provided an external skin preparation containing a core-shell structure, comprising a core portion containing a poorly water-soluble active ingredient and a solubilizing agent, and a shell portion containing a surfactant. The solubilizing agent is at least one selected from the group consisting of cyclodextrin, methyl-cyclodextrin, dimethyl-cyclodextrin, 2-hydroxypropyl-cyclodextrin, hydroxyethyl-cyclodextrin, sulfobutyl ether-cyclodextrin, glucosyl-cyclodextrin, maltosyl-cyclodextrin and cluster dextrin. The surfactant is at least one selected from the group consisting of glycerol fatty acid esters, sorbitan fatty acid esters, propylene glycol fatty acid esters and fatty acid alkanolamides. A mass ratio between the poorly water-soluble active ingredient and the solubilizing agent (poorly water-soluble active ingredient:solubilizing agent) is 1:0.1 to 1:30.

External skin preparation comprising a core-shell structure

A particle comprising a first fraction containing an active ingredient and a second fraction containing a surfactant, and having a number average particle diameter of from 1 to 100 nm.

Preparation

The present invention provides a core-shell structure having high skin permeability. The core-shell structure includes a core portion containing a hydrophilic drug having a molecular weight of 400 or more; and a shell portion containing a surfactant, and the core portion is a solid, the hydrophilic drug has a water-octanol partition coefficient of &#x2212;3 or more and 6 or less, the surfactant has an alkyl group or an alkenyl group having 10 to 20 carbon atoms, and a mass ratio between the hydrophilic drug and the surfactant (hydrophilic drug:surfactant) is 1:5 to 1:20.

Core-shell structure and topical agent

An object is to provide a formulation that includes a particle containing an active ingredient and a surfactant, and a base, and is more excellent in storage stability. For solution, a formulation including a particle containing an active ingredient and a surfactant, and a base, in which the surfactant is contained in a ratio of 5 to 100 parts by weight based on 1 part by weight of the active ingredient, is provided.

Formulation and method for producing same

An object of the present invention is to provide: a purified serum albumin having less lot-to-lot variation; and an immunoassay method utilizing the purified serum albumin, in which high reactivity and less non-specific reactions are achieved. The present invention provides a purified serum albumin, which is a serum albumin used as a blocking agent and/or in a suspension containing an insoluble carrier in an immunoassay method, and is composed mostly of a fraction, the fraction having an absorbance of not exceeding 9.0 mAbs when measured in the form of 1% aqueous solution at a wavelength of 463 nm by using a quarts cell having an optical path length of 1.0 cm.

Purified serum albumin, and immunological measurement method

Disclosed herein is an RNA virus infection inhibitor that is capable of effectively inhibiting humans from being infected with RNA viruses to prevent the occurrence of symptoms or, even when symptoms occur, to relieve the symptoms and is less likely to cause unexpected discoloration or discoloration under normal service conditions. The RNA virus infection inhibitor comprises an RNA virus infection-inhibiting compound comprising a linear polymer having, in its side chain, at least one of substituents having structural formulas represented by general formulas (1) to (3).

RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitor

Immunoassay reagent and immunoassay method

Growing community of inventors

Osaka, Japan

Takayuki Akamine